Home › Immunoglobulin Light-chain Amyloidosis
Immunoglobulin Light-chain Amyloidosis clinical trials recruiting in the U.S.
16 studies for Immunoglobulin Light-chain Amyloidosis are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA7 studies
- Rochester, MN5 studies
- Durham, NC4 studies
- New York City, NY4 studies
- Columbus, OH3 studies
- Cleveland, OH3 studies
By state
- Arizona3 studies
- California3 studies
- Florida3 studies
- Massachusetts7 studies
- Minnesota5 studies
- New York4 studies
- North Carolina4 studies
- Ohio5 studies
- Tennessee4 studies
- Texas3 studies
Recently updated studies
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05898646SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07850284A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06768489Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06569147Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05145816A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT05951816A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT07224672Teclistamab-Daratumumab in AL Amyloidosis
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Jul 13, 2026 · NCT07110844A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07081646Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06022939Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 23, 2026 · NCT01408225Collection of Samples and Clinical Data From Patients With Amyloid Diseases
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 1, 2025 · NCT00898235Molecular Imaging of Primary Amyloid Cardiomyopathy
Recruiting
Ages 18 to 99 · All sexes · Updated Nov 14, 2025 · NCT02641145Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RecruitingObservational study
Ages 40 and older · All sexes · Updated Aug 6, 2025 · NCT06365060From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.